Real-world six-month outcomes in patients switched to faricimab following partial response to anti-VEGF therapy for neovascular age-related macular degeneration and diabetic macular oedema
Background: Landmark studies reported on faricimab efficacy and safety predominantly in treatment naïve patients, but outcomes following switch from other anti-VEGF therapies are lacking. We evaluated patients switched to faricimab who had previously shown a partial response to other anti-VEGF injec...
Үндсэн зохиолчид: | Borchert, GA, Kiire, CA, Stone, NM, Akil, H, Gkika, T, Fischer, MD, Xue, K, Cehajic-Kapetanovic, J, MacLaren, RE, Charbel Issa, P, Downes, SM, De Silva, SR |
---|---|
Формат: | Journal article |
Хэл сонгох: | English |
Хэвлэсэн: |
Springer Nature [academic journals on nature.com]
2024
|
Ижил төстэй зүйлс
Ижил төстэй зүйлс
-
Age-related macular degeneration: suitability of optogenetic therapy for geographic atrophy
-н: Borchert, GA, зэрэг
Хэвлэсэн: (2024) -
Efficacy, Durability and Safety of Faricimab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Oedema: Lessons Learned from Registration Trials
-н: Helene O. Larsen, зэрэг
Хэвлэсэн: (2023-07-01) -
Two-wavelength fundus autofluorescence and macular pigment optical density imaging in diabetic macular oedema.
-н: Waldstein, S, зэрэг
Хэвлэсэн: (2012) -
Faricimab for the Treatment of Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration
-н: Lorenzo Ferro Desideri, зэрэг
Хэвлэсэн: (2023-05-01) -
Intravitreal Faricimab for Previously Treated Neovascular Age-Related Macular Degeneration
-н: Hang A, зэрэг
Хэвлэсэн: (2024-12-01)